REGENXBIO (NASDAQ:RGNX) Rating Increased to Moderate Buy at Raymond James

Raymond James upgraded shares of REGENXBIO (NASDAQ:RGNX) to a moderate buy rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research note on Wednesday, January 15th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average target price of $35.64.

REGENXBIO Trading Down 2.6 %

Shares of RGNX stock opened at $8.21 on Thursday. The company has a market cap of $406.72 million, a P/E ratio of -1.63 and a beta of 1.29. The firm has a fifty day moving average price of $8.11 and a 200 day moving average price of $10.10. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Redmile Group LLC lifted its position in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock valued at $11,422,000 after purchasing an additional 44,037 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after purchasing an additional 296,700 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of REGENXBIO by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after buying an additional 37,055 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of REGENXBIO by 84.8% in the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock valued at $3,586,000 after acquiring an additional 140,666 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.